Navigation Links
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
Date:7/2/2009

of these conditions (71% of these patients had no heart failure, 29% were in NYHA class I-III with stable heart failure). This trial showed that Multaq(R) (dronedarone) 400 mg BID, in addition to standard therapy, reduced the combined endpoint of cardiovascular hospitalization or death from any cause by 24% (p<0.001) when compared to placebo, meeting the study's primary endpoint. This reduction was generally consistent across study subgroups based on baseline characteristics or medications. Patients taking Multaq(R) had higher rates of diarrhea, nausea, bradycardia, QT-interval prolongation and cutaneous rash than patients taking placebo.

Initiation of Multaq(R) treatment is contraindicated in patients with severe heart failure (NYHA class IV) or NYHA Class II - III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic. This unstable population corresponds to the population of the ANDROMEDA trial in which patients receiving dronedarone had a greater than 2-fold increase in mortality compared to placebo.

The ATHENA and ANDROMEDA trials provided two sets of data supporting the assessment of the product's benefit risk ratio in two significantly different patient populations.

To ensure the use of Multaq(R) in the appropriate patient population, sanofi-aventis U.S. LLC also announced the launch of mPACT(TM) - Multaq(R) Partnership for Appropriate Care and Treatment - the Risk Evaluation and Mitigation Strategy (REMS) developed by sanofi-aventis U.S. LLC. The mPACT(TM) Partnership was developed to assist healthcare professionals (HCPs) with the identification of appropriate patients and to ensure the safe use of Multaq(R) while minimizing risk. The risk mitigation program consists of a Communication Plan for HCPs, a medication guide for patients and post-marketing surveillance.

"We are pleased that the FDA has granted approval of Mu
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
2. FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
3. FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
4. ClearWay Minnesota(SM) Board Approves Four Regional Grants
5. Department of Defense Approves ISSA as Fitness Education Provider to Military Spouses
6. FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
7. Treating Untreatable Brain Tumors: FDA Approves New Laser Surgery
8. FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets
9. Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill
10. Kaiser Permanente Approves $13 Million in Community Benefit Grants in First Quarter of 2009
11. FDA Approves Plan B Pill for 17-Year-Olds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... ... The FSH Society , the Massachusetts-based charity that has transformed the science ... of a collection of fundraising events this fall. From Boston to Los Angeles, each ... further FSHD research. , The list of 2015 fall events include: , ...
(Date:9/1/2015)... ... 2015 , ... METTLER TOLEDO is pleased to announce that ... Kit, EasySampler data is automatically transferred to, and reported with, the referring chemical ... , EasySampler fully automates the sampling process including sampling capture, quench ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... 9, 2015 from 5:00 to 8:00 pm at the Marriott Indianapolis Downtown, 350 ... with career opportunities will be attending from across the country. All specialties will ...
(Date:9/1/2015)... ... September 01, 2015 , ... Dr. Trace Curry successfully ... of Cincinnati. In the last month the FDA has approved two intra-gastric balloons, ... These procedures represent the first incisionless, reversible, weight loss procedures available to Americans. ...
(Date:9/1/2015)... ... September 01, 2015 , ... Elizabeth Callahan, MD, founder ... the first in the area to offer RADIESSE® filler treatment for volume loss in ... prominence of tendons and veins in the hands, delivering smooth, natural-looking results that can ...
Breaking Medicine News(10 mins):Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 4Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3
... the human body with about 200 billion new blood cells ... will develop into a T cell, red blood cell, or ... remains largely unknown. A research team led by scientists from ... a systematic approach to help decipher this circuitry, compiling a ...
... THURSDAY, Jan. 20 (HealthDay News) -- Adults who were children ... suicide than adults who grew up in intact families, according ... at 6,647 adults, including 695 who were younger than 18 ... females differently, they found. Men whose parents divorced when ...
... who are on long-term oxygen therapy (LTOT) have more ... new study by researchers in Sweden, COPD patients on ... cardiovascular disease and other non-respiratory ailments. The study,s results ... and treat them to help decrease the risk of ...
... HealthDay Reporter , WEDNESDAY, Jan. 19 (HealthDay News) -- ... determine whether a patient,s breast cancer has spread, especially ... have compared two approaches -- a sentinel lymph node ... dissection, which is a more invasive procedure that can ...
... Reporter , WEDNESDAY, Jan. 19 (HealthDay News) -- Stroke ... years while declining in the U.S. population at large, ... the AIDS-causing virus may put these patients at higher ... linking the medications to the higher stroke rate, but ...
... 2011) Following a competitive application process, Michele D. ... of Pediatrics, Children,s Hospital Los Angeles, was awarded a ... part of the Autism Treatment Network (ATN) as an ... supported by Autism Speaks, which is North America,s largest ...
Cached Medicine News:Health News:Global view of blood cell development reveals new and complex circuitry 2Health News:Global view of blood cell development reveals new and complex circuitry 3Health News:Parents' Divorce May Contribute to Suicidal Thoughts Years Later 2Health News:Causes of death shifting in patients diagnosed with COPD 2Health News:Small Spreads of Breast Cancer May Not Affect Survival 2Health News:Small Spreads of Breast Cancer May Not Affect Survival 3Health News:Stroke Risk May Be Higher in HIV Patients 2Health News:Children's Hospital Los Angeles joins Autism Treatment Network 2
(Date:8/31/2015)... VIEW, Calif. , Aug. 31, 2015 /PRNewswire/ ... for flow cytometry is experiencing a rise in ... the demand in underdeveloped nations to quantitate CD4 ... Logo - http://photos.prnewswire.com/prnh/20150831/262206LOGO ... Analysis of the Global Flow Cytometry Market ( ...
(Date:8/31/2015)... HARRISBURG, Pa. , Aug. 31, 2015 ... been reversed statewide since Pennsylvania ... the life-saving drug kits, naloxone. Heroin and ... in Pennsylvania , killing more individuals ... 2013, approximately 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... , Aug. 31, 2015  The departments of ... event today at Gaudenzia Concept 90 to raise awareness ... overdose crisis in Pennsylvania and ... and focus on recovery through the Building Bridges ... Pennsylvanians are dying every day to a disease that ...
Breaking Medicine Technology:Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2
... Phase 1 Colorectal and Prostate Cancer,Trials To Be ... FRANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, ... announced that data from a Phase 2 trial,of ... small cell lung cancer (SCLC) will be presented ...
... Urine Flow, With,Long Lasting Effect in Phase 2 ... Spectrum,Pharmaceuticals, Inc., today announced Phase 2 safety and ... the treatment,of benign prostatic hypertrophy (BPH), at the ... Convention Center in,Anaheim, California on Tuesday, May 22, ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 2Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 3Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 4Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 2Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 3Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 4Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: